Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Author： Ascierto Paolo A. Margolin Kim

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|11|1617-1619

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.11, 2014-06, pp. : 1617-1619

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

By Hersh Evan O’Day Steven Powderly John Khan Khuda Pavlick Anna Cranmer Lee Samlowski Wolfram Nichol Geoffrey Yellin Michael Weber Jeffrey

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 489-498

Springer Publishing Company

Access to resources Recommend Favorite

Lactitol may be more effective than conventional therapy for the treatment of gut-derived endotoxinaemia in patients with chronic viral hepatitis

Inpharma, Vol. 1, Iss. 1580, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

A Novel Treatment Approach for Extensive, Eruptive, Cutaneous Squamous Cell Carcinomas in a Patient Receiving BRAF Inhibitor Therapy for Metastatic Melanoma

By Fathi Ramin Kamalpour Loebat Gammon Bryan Tung Rebecca

Dermatologic Surgery, Vol. 39, Iss. 2, 2013-02 ,pp. : 341-344

Elsevier

Access to resources Recommend Favorite

Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

By Sharma Anant Shah Sachin R. Illum Henrik Dowell Jonathan

Drugs, Vol. 72, Iss. 17, 2012-12 ,pp. : 2207-2222

Adis International

Access to resources Recommend Favorite

The GVAX cancer vaccine plus ipilimumab is active in the treatment of patients with advanced prostate cancer

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite